Turkish Journal of Medical Sciences
Volume 33

Number 6

Article 4

1-1-2003

A Novel Method of Reporting c-erbB-2 Overexpression; Correlation
With Grade but not With Other Prognostic Parameters in Breast
Cancer
MUSTAFA SAMUR
ŞEYDA KARAVELİ
HAKAN BOZCUK
ELİF PESTERELİ
MUSTAFA ÖZDOĞAN

See next page for additional authors

Follow this and additional works at: https://journals.tubitak.gov.tr/medical
Part of the Medical Sciences Commons

Recommended Citation
SAMUR, MUSTAFA; KARAVELİ, ŞEYDA; BOZCUK, HAKAN; PESTERELİ, ELİF; ÖZDOĞAN, MUSTAFA; YILDIZ,
MUSTAFA; ARTAÇ, MEHMET; and SAVAŞ, BURHAN (2003) "A Novel Method of Reporting c-erbB-2
Overexpression; Correlation With Grade but not With Other Prognostic Parameters in Breast Cancer,"
Turkish Journal of Medical Sciences: Vol. 33: No. 6, Article 4. Available at: https://journals.tubitak.gov.tr/
medical/vol33/iss6/4

This Article is brought to you for free and open access by TÜBİTAK Academic Journals. It has been accepted for
inclusion in Turkish Journal of Medical Sciences by an authorized editor of TÜBİTAK Academic Journals. For more
information, please contact academic.publications@tubitak.gov.tr.

A Novel Method of Reporting c-erbB-2 Overexpression; Correlation With Grade
but not With Other Prognostic Parameters in Breast Cancer
Authors
MUSTAFA SAMUR, ŞEYDA KARAVELİ, HAKAN BOZCUK, ELİF PESTERELİ, MUSTAFA ÖZDOĞAN, MUSTAFA
YILDIZ, MEHMET ARTAÇ, and BURHAN SAVAŞ

This article is available in Turkish Journal of Medical Sciences: https://journals.tubitak.gov.tr/medical/vol33/iss6/4

Turk J Med Sci
33 (2003) 363-368
© TÜB‹TAK

EXPERIMENTAL / LABORATORY STUDIES

A Novel Method of Reporting c-erbB-2 Overexpression:
Correlation with Grade But Not with Other Prognostic
Parameters in Breast Cancer*

Mustafa SAMUR1, fieyda KARAVEL‹2, Hakan BOZCUK1, Elif PESTEREL‹2, Mustafa ÖZDOGAN1,
Mustafa YILDIZ1, Mehmet ARTAC1, Burhan SAVAfi1
1

Department of Medical Oncology, Faculty of Medicine, Akdeniz University, Antalya - Turkey
2

Department of Pathology, Faculty of Medicine, Akdeniz University, Antalya - Turkey

Received: May 02, 2003

Abstract: Overexpression of erbB-2 protein is a marker of clinically aggressive behavior in breast cancer patients. In general erbB2 status is reported on a scale from negative to 3+, depending on staining intensity, if more than 10% of the tumor cells are stained.
However, the original definition does not take into account the percentage of stained cells in detail, since all samples score in the
same way if they are above the cut-off, established at 10%. In this study, we evaluated the erB-B2 overexpression by
immunohistochemistry in 169 patients and evaluated any correlation with the other well known prognostic parameters. We also
tested whether there was a difference between the original definition of c-erbB-2 positivity (2+ or 3+) and a novel system, the total
c-erbB-2 score, which takes into account both the percentage, and intensity of staining as a continuous variable. The total c-erbB-2
score was correlated with the grade (P = 0.006) but not with other parameters. When 2+ and 3+ levels of staining together were
regarded as positive, a similar correlation with grade was demonstrated. However, when only 3+ cases were considered, there was
no significant correlation. In conclusion reporting c-erbB-2 as a continuous variable may make more sense than treating a cut-off
value as positive.
Key Words: c-erbB-2, HER-2/neu, breast cancer, grade

Introduction
The HER-2/neu gene encodes a tyrosine kinase
receptor, c-erbB-2, which is one of the members of the
epidermal growth factor receptor family. Although the
exact mechanism is not totally clear, it is believed that the
binding of a specific ligand to this receptor triggers
multiple pathways of intracellular signal transduction,
leading to increased tumorigenicity, invasion and
metastasis (1-2). Although the data are inconclusive,
overexpression of c-erbB-2 protein appears as a poor
prognostic factor in breast cancer and causes decreased
sensitivity to hormonal treatment and to CMF-based
chemotherapy and relatively higher sensitivity to

antracyclines (3-6). Correlation with other poor
prognostic factors also confirms that overexpression of cerbB-2 protein is a marker of clinically aggressive
behavior (7).
c-erbB-2 protein overexpression can be detected with
different methods. Fluorescence in situ hybridization
(FISH) is the most sensitive of these methods. However,
it is not readily available in every clinic. Although less
sensitive than FISH, immunohistochemical (IHC) assays
are widely used due to their availability and simplicity.
When reporting results, the degree of erbB-2 protein
overexpression measured by IHC is scored according to
the intensity of membrane staining and the percentage of
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tumor cells stained. A 2+ score denotes a weak to
moderate complete membrane staining in more than
10% of the tumor cells, whereas for a 3+ score strong
complete staining is needed in more than 10% of the
tumor cells. It is not known if there is a real difference
between 10% and 100% staining from a clinical point of
view. Studies on c-erbB-2 do not address the percentage
of positive staining in detail. In this regard, it is difficult
to compare different studies, because of different
definitions of positivity.
In this study, we evaluated c-erB-B2 overexpression
by IHC and looked for correlations with grade and other
well known prognostic parameters. We also evaluated
whether there was a difference between the original
definition of erBB-2 positivity (2+ or 3+) and a novel
system, which regards both the percentage and intensity
of staining as a continuous variable.

Materials and Methods
We retrospectively evaluated 169 previously operated
breast cancer patients admitted to the Medical Oncology
Department of Akdeniz University Medical School for
adjuvant chemotherapy between April 1998 and
September 2002. Information on age, menopausal
status, histological diagnosis, tumor diameter and axillary
lymph node status was obtained from the medical
records. Tumors were graded according to the modified
Bloom and Richardson method proposed by Elston and
Ellis (8).
Immunohistochemical Methods
Immunohistochemical staining was performed on
buffered formalin fixed, paraffin embedded tissue
sections. Sections 4 mm thick were mounted on poly-Llysine coated slides, deparaffinized and hydrated through
graded alcohols to water. Optimum pretreatment and
dilutions were determined by testing with known positive
and negative material. The slides were microwaved with
citrate buffer, pH = 6.6, for 10 min in an 800 W
microwave oven for antigen retrieval, then allowed to
cool for 20 min. The slides were stained on Dako
TechMate 500 automated immunostainer with the
standard streptavidin-biotin method. Following a
hydrogen peroxide block of endogenous peroxide and
incubation with proteinase K for 60 min, the slides were
incubated with primary antibodies, c-erbB2 (Clone e24001+3b5, 1:100 dilution, Neomarkers, CA, USA),
364

estrogen receptor (ER) (Clone 1D5, 1:50 dilution, Dako,
Denmark) and progesterone receptor (PR) (Clone
hPRa2+hPRa3, Neomarkers, CA, USA) for 60 min,
followed by brief buffer washes. The slides were then
treated with a Universal LSAB2 kit (K0675, Dako,
Denmark) and reacted with diaminobenzidine and
hydrogen peroxide to visualize the end product. Mayer’s
hematoxylin was used as a counter stain. Negative control
sections were incubated in PBS in place of the primary
antibody.
The magnitude of c-erbB-2 expression
c-erbB-2 was first defined along the original
recommendation of 2+ or 3+ (a 2+ score denotes a weak
to moderate complete membrane staining in more than
10% of the tumor cells, whereas for a 3+ score, strong
complete staining is needed in more than 10% of the
tumor cells). c-erbB-2 expression was also defined as a
continuous variable on a 300 (3 x 100) scale, basically as
a ratio, the denominator always being 300, and the
nominator being the product of the percentage of cell
staining (from 0 to 100) and the intensity of staining
(from 0+ to 3+), where 0 = no staining, 1 = faint
membrane staining, 2 = weak to moderate complete
membrane staining and 3 = strong complete membrane
staining. Cytoplasmic staining is considered non-specific
and negative. For example strong complete staining in
50% of cells gave a score of 3 x 50/300 = 150/300 = 0.5
whereas weak-moderate staining in 30% gave the result 2
x 30/300 = 60/300 = 0.2. We analyzed both of the
reporting methods of c-erbB-2 and searched for
correlations with the other classical prognostic factors.
Hormone receptor status was also evaluated as the ER and
the PR score as continuous variables, according to staining
intensity (weak, moderate and strong), and stained
percentage of cells as described above for c-erbB-2.
Statistical Analysis
The correlation of c-erbB-2 expression as a
continuous variable with grade and other continuous
clinical parameters was evaluated by the Spearman
correlation coefficient. c-erbB-2 overexpression in the
form of a categorical variable (3+ vs. other or 2-3+ vs.
other) in relation to the continuous variables in question
2
was evaluated by Mann-Whitney U test, and by the X test
if in relation to categorical variables. A P value of <0.05
was considered statistically significant. SPSS 10.0
software was used for the analysis.
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Results

1,2

We included 169 breast cancer patients aged between
26 and 70 (median 44) in our study. Of our patients,
67% were premenopausal. Two-thirds of our patients
had at least 1 positive axillary lymph node, and 57% of
the samples were ER positive, 42% were c-erbB-2/3+
and most of them were either grade 2 (55.4%) or 3
(38.9%). Details of tumor characteristics are given in
Table 1.

1,0

When evaluated as a continuous variable, the total cerbB-2 score was positively correlated only with grade (P
= 0.006). (Table 2 and Figure ). On the other hand, when
the original definition of 3+ staining only was accepted as
positive and the others as negative, as categorical
variables, correlation with grade was not statistically
2
significant (X = 3.568, df = 1, P = 0.059). When the
combination of 2+ and 3+ staining tumor samples was
treated as positive, correlation with grade was again
apparent (X2 = 7.512, df = 1, P = 0.006) (Table 2).
There was a strong correlation between ER and PR
scores and between tumor size and hormone receptors,
as detailed in Table 2.
Table 1. Patient characteristics.
N (%)
Age
Premenopausal
Postmenopausal
ER+
PR+
ER score
PR score
Erbb-2, 2+
Erbb-2, 3+
Erbb-2 score
Grade
1
2
3
Tumor size (T)
1
2
3
Axillary LAP (N)
0
1-3
>3

Mean (min-max)

Median

45 (26-70)

44

113 (66.8)
56 (33.1)
97 (57.4)
80 (47.3)
0.26 (0-0.95)
0.17 (0-0.90)
28 (16.5)
71 (42.0)
0.41 (0-1.00)
9 (5.7)
87 (55.4)
61 (38.9)
35 (21.1)
104 (62.6)
27 (16.3)
58 (34.9)
57 (34.4)
51 (30.7)

0.40

ERBSCORE

,8
,6
,4
,2
0,0
-,2
N=

9
1

87
2
GRADE

61
3

Figure. c-erb-B2 score with respect to grade.

Discussion
HER2/neu is amplified in approximately 30% of
breast tumors, causing receptor overexpression, and is
generally regarded as a poor prognostic factor (9-10). In
our study a higher percentage of patients overexpressed
erbB-2 (42%, 3+) compared to the literature. This may
be due to the patient properties of our study-group
representing, an advanced stage. Nearly 65% of our
patients had axillary lymph node metastasis. Another
explanation may be the different disease profile between
eastern and western countries. Moreover, this
discrepancy might be due to the antibody used in our
study which is a different one to those the ones used in
trastuzumab trials (11).
Many studies have investigated the correlation of cerbB-2 protein overexpression with the other
prognosticators, as well as its role as a predictor of
clinical outcome with different types of therapies.
However, its value as a prognostic and predictive factor is
still not conclusively established. Different testing
methods, heterogeneous and small patient populations
and retrospective analyses cause major problems in
comparing different studies. The method of reporting
results of c-erbB-2 positivity might also have caused an
inconsistency in the interpretation of the results. In most
studies that use immunohistochemical methods c-erbB-2
protein expression was reported as positive or negative as
a categorical variable, and the degree of positivity
(percentage of stained cells and intensity together) was
not taken into account. In some reports, >1% staining
was accepted as positive (6), whereas in others a 10%
cut-off was chosen as originally defined (12), or even
50% of tumor cells were required to be stained positively
365
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Table 2. Correlations between c-erbB-2 score and other clinical and pathologic variables.
Correlation coef.
P value

c-erbB-2

PRscore

ERscore

Grade
score

Axillary
LAP (n)

PR-score

.086
.269

ER-score

.109
.159

.461
.000*

Grade

.220
.006*

-.023
.774

-.040
.618

Axillary LAP

-.064
.413

-.058
.461

-.010
.900

-.034
.675

Tumor size

-.060
.446

-.198
.011*

-.286
.000*

.135
.094

.148
.060

Age

.068
.378

-.099
.202

.107
.167

.005
.955

-.063
.417

Tumor
size

-.145
.063

* Correlation is significant at the .05 level (2-tailed).

to be regarded as positive (3-4). As a result, 2%, 11%
and 100% complete strong staining of tumor cells were
all deemed to be erbB-2 positive in the above mentioned
studies, although there is no scientific proof that these
are all the same. It is possible that both the magnitude of
positivity and the percentage of tumor cells staining
positive may have an impact. Such a relation has already
been demonstrated for estrogen receptor. The Early
Breast Cancer Trialists’ Collaborative Group overview
showed that tamoxifen has greater benefits in women
with strongly positive ER levels, than in those with
moderate levels (13).
Addressing the potential prognostic significance of
HER-2 gene amplification, Slamon et al. demonstrated
that the numbers of gene copies are important (14).
Patients who had 5 or more gene copies had a shorter
relapse-free survival than those who had 2 or more
copies and those with no gene amplification (37%, 56%
and 60%, respectively). This frequently cited study is the
first report of HER-2 gene amplification as a prognostic
factor. We also think that this study is important because
it demonstrates a survival difference with regard to the
degree of amplification.
In this study, we define a novel method of reporting
c-erbB-2 results. In our patients we evaluated c-erbB-2
366

both as a categorical variable (2+ or 3+ or negative as
defined originally) and as a total c-erbB-2 score calculated
by intensity multiplied by the percentage of cells stained
divided by 300. We analyzed the potential utility of these
2 different approaches. As a result, in both methods, cerbB-2 was correlated with grade. These results are
compatible with those of most others, showing that cerbB-2 positivity is related to more aggressive tumor
behavior in relation to grade (15-17). However, in our
patients relation with grade was not significant when 3+
cases only were accepted as positive. On the other hand,
it was significant when the erbB-2 score was used as a
continuous variable and when both 2+ and 3+ cases were
treated as positive. This finding is an indication that the
percentage of tumor cells stained positive may be of
importance. There may be a prognostic and predictive
difference between 10% staining and 100% staining.
One recent study showed that there is an association
between hormonal receptors and Her-2/neu protein
when both were quantitatively measured with enzymelinked immunosorbent assay and evaluated as continuous
variables (18). It therefore may be justified to report the
results as a c-erbB-2 score when the IHC method is used
and to make further evaluations in homogenously treated
patient populations to establish whether this score has a

M. SAMUR, fi. KARAVEL‹, H. BOZCUK, E. PESTEREL‹, M. ÖZDOGAN, M. YILDIZ, M. ARTAC, B. SAVAfi

prognostic and predictive impact. It would be also
worthwhile evaluating whether different percentages of
strong complete staining predict a response to
trastuzumab.
We did not find any relation between hormone
receptor status and c-erbB2 overexpression, nor any
relation between axillary lymph node status, age and
menopause. In the literature, a positive correlation and a
lack of correlation were both reported in this regard (1925). The reason for this discrepancy may be the different
methods of detecting c-erbB-2 overexpression and
hormone receptor status. Another reason may be the
different definitions of c-erbB2 and ER/PR positivity, as
mentioned above.

to analyze data from various centers more
homogenously. We think that when IHC methods are
used to evaluate c-erbB-2 expression, studies reporting cerbB-2 expression as a continuous variable, instead of
reporting as positive/negative with different cut-off
values, will be more suitable for exploring both the
prognostic and predictive values of c-erbB-2, and will
make it easier to compare different studies or to evaluate
them in a meta-analysis. In short, we believe our results
justify further evaluation of our novel method of c-erbB2 reporting in a clinical setting.

Corresponding author:
Mustafa SAMUR
Akdeniz University, Faculty of Medicine
Internal Medicine Dep. Division of Medical Oncology
Antalya - Turkey
e-mail: msamur@akdeniz.edu.tr

In conclusion, different methodologies in both
measuring and reporting c-erbB-2 positivity still pose a
problem and consensus on a universally accepted
standard is urgently needed. Such a consensus may help
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